Roche Pharmaceutical Development and Sales Overview

YTD Sep 2022: Solid underlying sales growth in both divisions Pharma Quarterly sales evolution 2021-2022 Diagnostics Quarterly sales evolution 2021-2022 Roche % CER % CER +55% +55% +48% +55% +45% +45% +35% +35% +31% +24% +25% +25% +17% +18% +14% +15% +15% +9% +4% +5% +6% +6% +7% +5% +2% +5% +11% +3% +10% +7% +8% -5% -9% +2% -0% -5% 0% -1% -3% -6% -4% -13% -15% -15% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021 vs. 2020 2022 vs. 2021 2021 vs. 2020 2022 vs. 2021 -Pharma Underlying business -Diagnostics -Diagnostics Base business Growth rates at CER (Constant Exchange Rates); 1 Excl. Ronapreve and Actemra 10 10

View entire presentation